There are some questions that have not found answers. Effects of different doses of boric acid intake on body weight must be evaluated. Additionally the effects of low dose oral boric acid intake on different kind of laboratory animals (such as rats, rabbits) must be evaluated, especially the mechanism of action. For this reason we are planning a full complement of boric acid dose as well as other kinds of studies on animal. We will perform cell proliferation assay and real time PCR analyses on adipose tissue derived mesenchymal stem cells for evaluation of molecular changes in the adipose tissue level.
It should be noted that in theory if one was to consistently suppress your natural estrogen levels for a long period of time, this would negatively impact your health, including your cholesterol. Due to the ability of Letrozole- to inhibit estrogen so much, this should definitely be a concern to most users. However the research that has focused on the relationship between use of letrozole and cholesterol levels is rather inconsistent in it's findings. Many studies have concluded that the compound is detrimental to both a user's HDL and LDL cholesterol levels, while other research has found no link. Obviously individuals are best served to monitor their cholesterol while using any compound via blood tests however barring that, letrozole should simply not be run for extended periods of time if at all possible. Doing so could cause serious medical complications.
Along with the issues related to blood lipids is the fact that many users complain that their libido is dramatically reduced when using the compound. This is related to the fact that estrogen is partly responsible for the regulation of an individual's sex drive. Since Letrozole- is so potent it can often drive estrogen levels too low and this inhibits a user's libido. To avoid this users can lower dosages, but some anecdotally report that even extremely low doses of the drug can cause problems. If this is the case a less potent compound such as exemestane or anastrozole may be a more appropriate option.
A 2006 double-blind , randomized controlled trial indicated ondansetron may have value in the treatment of schizophrenia, as an adjunct to haloperidol . The study found the combination to significantly improve negative schizophrenia symptoms, and people taking both drugs experienced fewer of the adverse effects commonly associated with haloperidol.  An earlier, smaller, open-label trial had found ondansetron to be useful in treating antipsychotic -induced tardive dyskinesia in people with schizophrenia, and the study patients also showed significant improvement in the disease's symptoms.